About MedPacto
MedPacto is a publicly listed company based in Suwon (South Korea) founded in 2013. Small molecule inhibitors for cancer are developed by MedPacto. MedPacto has raised $16 million across 2 funding rounds. The company has 57 employees. Its chief executive, as recorded, is Seong-Jin Kim. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
MedPacto is engaged in business activities that are not detailed on the website. No specific information regarding sectors, solutions, or operational focus is provided in the available content.
- Headquarters Suwon, South Korea
- Employees 57
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website medpacto.com
- Legal Name Medpacto, Inc.
- Annual Revenue$2.7 M (USD)as on Dec 31, 2025
- Net Profit-$8.87 M (USD)36.39as on Dec 31, 2025
- EBITDA-$8.93 M (USD)36.4as on Dec 31, 2025
- Total Equity Funding$16M (USD)
in 2 rounds
- Latest Funding Round$90.24M (USD), Post-IPO
Dec 2020
- Employee Count57
Funding Insights of MedPacto
MedPacto has successfully raised a total of $16M across 2 strategic funding rounds. The most recent funding activity was a Post-IPO round of $90.24 million completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $16M
- Total Rounds 2
- Last Round Post-IPO — $90.24M
- First Round $16M
(Jun 2018)
All 2 funding rounds of MedPacto with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2020 | $90.24M | Post-IPO | – | – | – |
| Jun 2018 | $16M | Series A | – | – | – |
People of MedPacto
1 people are tracked at MedPacto (1 in leadership); the tracked headcount is 57.
| Name | Role | Group |
|---|---|---|
Seong-Jin Kim | CEO | Leadership |
Complete people profiles for MedPacto
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of MedPacto
MedPacto is a publicly listed company on the KRX with ticker symbol 235980 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date19 Dec 2019
- Listed onKRX: 235980
- Listed entityMedPacto, Inc.
- Exchange sectorHealth technology
- ISINKR7235980000
- Share price2,870.00 KRW (-1.88% on the day) · 2026-10-14
- Market capitalisation100,254,725,361.00 KRW
- EPS (diluted, trailing year)-412.52 KRW
- Volume (last session)62,928
Financials of MedPacto
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 3.90B KRW | -12.81B KRW | -12.89B KRW |
| 2024 | -20.14B KRW | -20.27B KRW | |
| 2023 | -35.32B KRW | -26.92B KRW | |
| 2022 | -35.75B KRW | -35.38B KRW | |
| 2021 | -17.04B KRW | -27.74B KRW |
Detailed financial statements for MedPacto
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of MedPacto
4 dated milestones of MedPacto across 7 years, from founding to its latest funding, stage changes and deals.
- Founded MedPacto is founded.
- Funding First funding round of $16.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $90.2M.
Web traffic of MedPacto
The website of MedPacto (medpacto.com) receives about 3K visits a month and ranks #4,215,585 among all websites worldwide, #5,207 in Biotechnology and Pharmaceuticals.
- Monthly visits3K
▼ 34.4% vs previous month
- Unique visitors2.1K
per month
- Global rank#4,215,585
among all websites
- Category rank#5,207
Health · Biotechnology and Pharmaceuticals
- Bounce rate36%
- Pages per visit1.4
- Average visit11 sec
- DevicesDesktop 27% · Mobile 73%
Websites whose visitors overlap most with MedPacto. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| medigatenews.com | 100% | #143,063 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Medpacto
Complete news archive for MedPacto
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MedPacto
MedPacto was founded in 2013 and raised its 1st funding round 5 years after it was founded.
MedPacto is headquartered in Suwon, South Korea. It is registered at Suwon, Gyeonggi, South Korea.
Seong-Jin Kim is the CEO of MedPacto, as recorded in our data.
MedPacto is a funded company, having raised a total of $16M across 2 funding rounds to date. The company's 1st funding round was a Series A of $16M, raised on Jun 2018.
MedPacto has 57 employees.
Annual revenue of MedPacto is $2.7M as on Dec 31, 2025.
MedPacto is engaged in business activities that are not detailed on the website. No specific information regarding sectors, solutions, or operational focus is provided in the available content.
Yes, MedPacto is publicly traded on KRX under the ticker symbol 235980.